GENAERA REPORTS EVIZON DATA

A A

Genaera has reported the results of Phase II trials of Evizon (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD).

The trials indicated that intravenous Evizon consistently stabilized or improved vision in both eyes in a dose-responsive fashion. The most recent data described outcomes for subjects in these studies with fellow affected eyes (i.e., documented disease in the second eye) and poor vision at study entry, and suggest that the treatment may benefit some patients with wet AMD whose vision has already significantly deteriorated.